PLX - AMEX

Protalix BioTherapeutics, Inc.

PLX·AMEX

$2.01

+1.8%

HealthcareBiotechnology

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$161.95M

EPS-0.0841

P/E Ratio-23.90

Earnings Date08/13/2026

82.35M

Assets

12%

3Y+48.0%

5Y+21.0%

10Y-

34.12M

Total Liabilities

13%

3Y-49.0%

5Y-64.0%

10Y-63.0%

48.23M

Total Equity

12%

3Y-553.0%

5Y-278.0%

10Y-584.0%

Protalix BioTherapeutics, Inc. Funding & Solvency Profile

PLX · AMEX

Current Assets

Cash & Cash Equivalents14.68M

Net Receivables8.84M

Inventory25.73M

Other Current Assets1.44M

Total Current Assets67 M

Non-Current Assets

Property, Plant & Equipment12.58M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets578.00K

Total Non-Current Assets13 M

Total Assets

82.35M

Financial Health Analysis

Current Ratio

2.51x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.71x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

40 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

81% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Protalix BioTherapeutics, Inc. Balance Sheet

PLX • AMEX

Protalix BioTherapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	14.7M	19.8M	23.6M	17.1M	39M	18.3M	17.8M	37.8M	51.2M	63.3M	76.4M	54.8M	86.4M	52M	27M	35.9M	81.3M	42.6M	61.8M	15.4M
Short-Term Investments	15.6M	15.1M	20.9M	5.1M	0.0	20.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	30.3M	34.8M	44.6M	22.2M	39M	38.5M	17.8M	37.8M	51.2M	63.3M	76.4M	54.8M	86.4M	52M	27M	35.9M	81.3M	42.6M	61.8M	15.4M
Net Receivables	8.8M	2.9M	5.3M	4.6M	3.4M	2M	4.7M	4.7M	1.7M	693K	0.0	1.9M	2.1M	1.4M	1.4M	9.2M	2.1M	793K	1.4M	1.3M
Accounts Receivables	8.8M	2.9M	5.3M	4.6M	3.4M	2M	4.7M	4.7M	1.7M	693K	0.0	1.9M	2.1M	1.4M	1.4M	9.2M	2.1M	793K	1.4M	1.3M
Inventory	25.7M	21.2M	19M	16.8M	18M	13.1M	8.2M	8.6M	7.8M	5.2M	5.8M	6.7M	8M	4M	279K	1.2M	0.0	0.0	0.0	0.0
Prepaids	394K	500K	444K	774K	905K	841K	314K	453K	433K	416K	408K	369K	286K	251K	235K	0.0	0.0	0.0	0.0	0.0
Other Current Assets	1.4M	596K	611K	536K	380K	1.3M	1.5M	1.4M	1.5M	2.2M	3.3M	2.2M	1.2M	3.4M	3.6M	0.0	0.0	0.0	0.0	0.0
Total Current Assets	66.7M	60.1M	69.9M	44.9M	61.7M	55.7M	32.5M	53M	62.7M	71.9M	85.9M	65.5M	97.9M	61.2M	32.5M	46.3M	83.4M	43.4M	63.2M	24.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	12.6M	10M	10.9M	9.6M	9.9M	10.4M	11M	6.4M	7.7M	8.7M	9.7M	11.3M	13.7M	16.3M	18.3M	17.5M	14.5M	6.8M	4.5M	2.4M
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1M	0.0	0.0	0.0	0.0	0.0
Tax Assets	2.5M	2.9M	3.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	578K	462K	528K	1.3M	2.1M	1.8M	2M	1.8M	1.9M	1.7M	1.6M	1.7M	1.7M	1.2M	0.0	942K	724K	581K	464K	293K
Total Non-Current Assets	15.7M	13.3M	14.5M	10.9M	12M	12.2M	12.9M	8.1M	9.6M	10.4M	11.4M	13M	15.4M	17.6M	19.3M	18.4M	15.3M	7.4M	5M	2.7M
Total Assets	82.3M	73.4M	84.4M	55.8M	73.7M	67.9M	45.4M	61.1M	72.2M	82.2M	97.3M	78.5M	113.3M	78.7M	51.8M	64.7M	98.7M	50.8M	68.1M	27M
LIABILITIES
CURRENT LIABILITIES
Total Payables	11M	11.1M	4.3M	5.9M	7.5M	7.7M	7.3M	5.2M	7.5M	4.2M	3.6M	3.8M	5.3M	5.3M	5.1M	6.3M	3.4M	2.2M	899K	892K
Accounts Payable	5.3M	4.5M	4.3M	5.9M	7M	7.2M	6.5M	5.2M	7.5M	4M	3.6M	3.8M	5.3M	5.3M	5M	6.3M	3.4M	2.2M	899K	892K
Other Payables	5.8M	6.6M	0.0	0.0	522K	482K	757K	0.0	0.0	226K	0.0	0.0	0.0	0.0	89K	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	11.8M	11.2M	13.2M	1.2M	14.4M	11.9M	9.4M	1.1M	8.8M	5.9M	1.1M	1.2M	1.6M	1.7M	6.2M	0.0	0.0	1.4M	2.9M	1.4M
Short Term Debt	0.0	0.0	21.7M	0.0	0.0	58.5M	4.3M	0.0	5.9M	53.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	1.4M	1.5M	1.4M	1.1M	1.2M	1.4M	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	3.5M	2.9M	530K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	13.2M	8.6M	5.4M	16.3M	9.9M	26.9M	837K	504K	6.8M	9.4M	9.4M	6.1M	4.6M	4.6M	0.0	0.0	0.0
Other Current Liabilities	2.3M	1.8M	4.9M	11.1M	1.5M	1.5M	1.8M	9.2M	526K	1.4M	6M	14.4M	10.5M	9.3M	1.2M	8.1M	13.6M	1.9M	0.0	0.0
Total Current Liabilities	26.5M	25.6M	45.5M	32.4M	33.2M	86.5M	40.2M	25.4M	22.8M	66.2M	11.2M	26.2M	26.7M	25.8M	18.7M	18.9M	21.5M	5.5M	3.8M	2.3M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	28.2M	27.9M	0.0	51M	48M	46.3M	23.6M	72.1M	67.5M	67M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	11.8M	1.7M	17M	33M	26.9M	0.0	744K	37.2M	41.8M	48.9M	50.9M	55.5M	60M	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4M	2.6M	0.0	0.0	2.3M	2.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	661K	559K	714K	1.6M	2.5M	2.3M	3.1M	7.7M	7.6M	2.3M	2.3M	3.2M	4.7M	7.4M	8.3M	1.7M	1.2M	937K	690K	436K
Total Non-Current Liabilities	7.6M	4.6M	5.3M	34M	46.5M	8.5M	75.5M	88.7M	80.8M	26M	75.1M	107.9M	113.6M	56.3M	59.2M	57.1M	61.3M	937K	690K	436K
Capital Lease Obligations	8.3M	5.5M	6M	5.3M	5.6M	5.9M	5.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	34.1M	30.2M	50.9M	66.4M	79.7M	95M	115.7M	114M	103.5M	92.2M	86.4M	134.1M	140.3M	82.1M	77.9M	76.1M	82.8M	6.5M	4.5M	2.7M
SHAREHOLDERS' EQUITY
Common Stock	80K	76K	73K	54K	46K	35K	15K	148K	144K	124K	100K	94K	93K	93K	86K	81K	81K	76K	76K	62K
Additional Paid-In Capital	433.1M	421.5M	415M	379.2M	368.9M	320.3M	270.5M	269.5M	266.5M	202.6M	194.1M	185.6M	184.3M	180.1M	145.8M	124M	122.3M	119.3M	106.6M	44.4M
Retained Earnings	-385M	-378.4M	-381.5M	-389.9M	-374.9M	-347.4M	-340.8M	-322.6M	-297.9M	-212.7M	-183.3M	-241.3M	-211.4M	-183.6M	-172M	-135.4M	-106.5M	-75M	-43M	-20.5M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-29.1M	-27.5M	-25.6M	-183.3M	-241.3M	-18.3M	-14.8M	-11.1M	-7.6M	-4.7M	-2.9M	-1.6M	355K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25.6M	0.0	241.3M	0.0	0.0	11.1M	7.6M	0.0	0.0	0.0	0.0
Total Stockholders' Equity	48.2M	43.2M	33.6M	-10.6M	-6M	-27M	-70.3M	-52.9M	-31.3M	-10M	10.9M	-55.6M	-26.9M	-3.4M	-26.1M	-11.3M	15.9M	44.3M	63.7M	24.3M
Total Equity	48.2M	43.2M	33.6M	-10.6M	-6M	-27M	-70.3M	-52.9M	-31.3M	-10M	10.9M	-55.6M	-26.9M	-3.4M	-26.1M	-11.3M	15.9M	44.3M	63.7M	24.3M
SUMMARY
Total Liabilities & Equity	82.3M	73.4M	84.4M	55.8M	73.7M	67.9M	45.4M	61.1M	72.2M	82.2M	97.3M	78.5M	113.3M	78.7M	51.8M	64.7M	98.7M	50.8M	68.1M	27M
Total Investments	15.6M	15.1M	20.9M	5.1M	0.0	20.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1M	0.0	0.0	0.0	0.0	0.0
Total Debt	8.3M	5.5M	27.7M	33.5M	33.5M	64.4M	60.9M	48M	52.2M	77.5M	72.1M	67.5M	67M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt	-6.4M	-14.2M	4.1M	16.4M	-5.5M	46.1M	43.1M	10.2M	1M	14.2M	-4.3M	12.7M	-19.4M	-52M	-27M	-35.9M	-81.3M	-42.6M	-61.8M	-15.4M
Shares Outstanding	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181	80,421,181

SEC Filings

PLX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 21, 2026	May 21, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	June 25, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 18, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 18, 2026	March 18, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 09, 2026	March 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 11, 2026	February 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 30, 2026	January 30, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 05, 2026	January 05, 2026	2026	View Filing

Showing 1 to 10 of 480 filings

Related Guides

Blog Categories

Continue your PLX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.